DJIA 16,493.52 93.85 0.57%
NASDAQ 4,384.35 68.28 1.58%
S&P 500 1,927.62 23.61 1.24%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)

107.48 2.71 (2.59%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VRTX $107.48 2.59%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $105.86
Previous Close $104.77
Daily Range $104.51 - $107.51
52-Week Range $58.06 - $116.88
Market Cap $25.6B
P/E Ratio -52.65
Dividend (Yield) $0.00 (0.0%)
Volume 256,857
Average Daily Volume 2,047,490
Current FY EPS -$2.72

Sector

Healthcare

Industry

Drugs

Vertex Pharmaceuticals (VRTX) Description

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website: http://www.vrtx.com/

News & Commentary

180 Million People Have This Disease, Yet Few Are Aware of It

75% of people with this potentially deadly disease are clueless they have it. Yet the interesting thing is we have the tools needed to practically eradicate it.

Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? - Analyst Blog

Will Biogen Idec (BIIB) Pull a Surprise this Earnings Season? - Analyst Blog

Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst

Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog

Bank Of America Is Impressed By Takeaways From Vertex Pharmaceuticals Conference Call

Nasdaq 100 Movers: TSLA, VRTX

3 Stocks Improving Performance Of The Drugs Industry

UPDATE: Piper Jaffray Upgrades Vertex Pharmaceuticals Ahead Of Expected Combination Approvals

Big Swings in Biotech Short Interest

Gilead Sciences, inc. Stock's Green Light Sparks Offensive

Gilead Sciences will need to convince healthcare payers to prescribe its new hepatitis C drug Harvoni.

See More VRTX News...

VRTX's Top Competitors

VRTX $107.48 (2.59%)
Current stock: VRTX
AMGN $139.56 (1.49%)
Current stock: AMGN
GILD $104.30 (2.04%)
Current stock: GILD
BIIB $321.17 (3.13%)
Current stock: BIIB